Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study identifies predictors of HIV drug resistance in patients beginning triple therapy

14.01.2005


The best method for preventing HIV patients from developing drug resistance is a careful, dedicated adherence to their prescribed drug regimen, according to a long-term, large-scale study presented today in New York City at the American Medical Association Media Briefing, HIV/AIDS, The Drug Resistance Epidemic. Other key predictors of resistance include measures of how much virus was present in a person’s bloodstream at the start of therapy and how much their immune status was compromised.



"We have a lot of studies showing that triple therapy works, as well as a lot of good information on the problem of resistance developing in triple antiretroviral therapy," said Richard Harrigan, Ph.D., director of the British Columbia Centre for Excellence in HIV Research Labs at St. Paul’s Hospital in Vancouver and lead author of the paper. "The problem with past studies is that they were limited to people in clinical trials and as people drop out they are lost to the study. In this study, we followed people beginning initial triple therapy for 30 months and were able to really get a sense of how the therapy works outside of clinical trials."

Triple therapy for HIV/AIDS is designed to hit the virus with three or more antiretroviral drugs from two or more different classes at once in order to reduce the viral load (amount of virus circulating in the blood) so drastically that the virus is not replicating enough to mutate and become resistant to the drugs designed to fight it, Dr. Harrigan explained.


Researchers in the study, published in the Feb. 1, 2005 issue of the Journal of Infectious Diseases, followed more than 1000 people who were beginning HIV triple therapy for the first time through 30 months of treatment. A number of factors, including adherence to their prescribed medication regimen, age, gender, plasma viral load, CD4 count, year of initial therapy and history of injection drug use were examined for their impact on the development of resistance.

Of all the factors studied, adherence to the medication regimen (measured by the number of filled prescriptions) had by far the greatest impact on the development of resistance, the study showed. To test adherence, patients were divided into groups according to what percentage of their prescriptions they filled, 0-20 percent, 20-40 percent, 40-60 percent, 60-80 percent, 80-90 percent, 90-95 percent and 95 percent or more. Patients who missed less than five percent of their medications did not develop resistance over the course of the study.

"Those who took 80 percent of their medication were likely to develop resistance most quickly. This probably means that they are taking enough medication to create a selective pressure," Dr. Harrigan said. "Which means that resistant virus mutations still have an opportunity to replicate instead of reducing the viral load to levels so low it can’t replicate at all."

"The good news is that although they require a very high level of adherence, these therapies do work," Dr. Harrigan said. "And things have only gotten better in the time since this study was completed. We have more and better drugs and a better understanding of how to give them. We are working to make taking them as simple as possible."

Gavin Wilson | EurekAlert!
Further information:
http://www.providencehealth.bc.ca
http://www.ama-assn.org

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>